KOSDAQChemicals120240

Daejung Chemicals & Metals

₩13,900▼ 0.43%2026-11-18 close
Market Cap
₩99.9B
Turnover
₩89,177,230
Volume
6.4K
Shares out.
7.2M
PER
6.3×
PBR
0.6×
EPS
₩2,362
Dividend Yield
3.20%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩475 per share · Prices as of the 2026-11-18 close

01

Report overview

Domestic Reagent Specialist: Checking the 2026 Earnings Trend

Daejung Chemicals & Metals recovered its operating profit in 2025 on the disclosed figures and improved through Q2 2026, but Q3 2026 operating profit edged down from a year earlier.

  1. 1

    On disclosed figures, 2025 revenue of KRW 108.1 billion was the largest year in 2022-2025, and operating profit recovered from KRW 8.48 billion in 2024 to KRW 11.2 billion.

  2. 2

    Q2 2026 operating profit of KRW 5.26 billion was the highest of the last five quarters, and reports attribute part of the demand to expanded government-funded projects.

  3. 3

    Q3 2026 operating profit of KRW 3.56 billion fell 2.4% from the year-earlier quarter, which marks a slowdown in the recovery.

  4. 4

    Operating cash flow fell to KRW 9.97 billion in 2025 from KRW 12.8 billion in 2022, so the gap between earnings and cash generation is a key item to watch.

  5. 5

    At the end of 2025 the debt ratio was 14.7% and total equity stood at KRW 183.6 billion, indicating a light debt burden.

02

Business structure

Daejung Chemicals & Metals was founded in 1986 and produces and sells general, analytical, diagnostic and special test reagents, electronic-grade solvents and active pharmaceutical ingredients in Korea and overseas (company profile coverage, around 2022).

Reagents are the core business, and a listing-stage report from around 2010 described reagents as roughly 70% of total sales. The company is reported to supply about 5,000 domestically produced reagents and about 25,000 global-brand reagents (coverage around 2022).

Major customers reported in the same coverage include chemical makers such as LG Chem, Hanmi Fine Chemical and Hyosung, and pharmaceutical companies such as Chong Kun Dang and Boryung. New businesses such as food additives, cosmetic materials and high-purity HPLC solvents were mentioned in coverage from around 2013.

A battery-precursor subsidiary was reported in around 2013, in which the parent held a 24.95% stake. The parent supplied cobalt, manganese and nickel feedstock to that subsidiary under the same arrangement.

Domestic reagent sales have been described as an oligopoly shared by three companies, including Samjeon Pure Chemical and Deokeon Pharmaceutical (coverage around 2017). A FnGuide summary of Q1 2026 attributed higher reagent demand to expanded government-funded projects.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩29.1B₩3.7B12.5%
2025Q4₩28.4B₩3B10.7%
2026Q1₩29.5B₩4B13.5%
2026Q2₩32.3B₩5.3B16.3%
2026Q3₩29.8B₩3.6B11.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩96.6B₩11.6B₩13.7B12.0%9.4%18.5%
2023₩93.3B₩11B₩13B11.8%7.8%17.8%
2024₩92.3B₩8.5B₩9.7B9.2%5.6%16.8%
2025₩108.1B₩11.2B₩13.5B10.3%7.4%14.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On disclosed annual figures, revenue went from KRW 96.6 billion in 2022 to KRW 93.3 billion in 2023 (down 3.4%) and KRW 92.3 billion in 2024 (down 1.0%), before rising to KRW 108.1 billion in 2025 (up 17.1%). 2025 was the largest year of 2022-2025 for revenue, and 2024 was the smallest.

Operating profit fell from KRW 11.6 billion in 2022 to KRW 8.48 billion in 2024 (down 22.9% year on year), then recovered to KRW 11.2 billion in 2025 (up 31.9%). 2022 was the largest year for operating profit, and 2024 the smallest.

The operating margin was 12.0% in 2022, 11.8% in 2023, 9.2% in 2024 and 10.3% in 2025, so 2024 was the low point.

Net profit attributable to controlling shareholders was KRW 13.7 billion in 2022, KRW 13 billion in 2023 (down 5.7%), KRW 9.68 billion in 2024 (down 25.3%) and KRW 13.5 billion in 2025 (up 40.0%), close to the 2022 level. Total net profit matched the controlling-shareholder figure in each year.

Operating cash flow fell from KRW 12.8 billion in 2022 and KRW 14.4 billion in 2023 to KRW 9.97 billion in 2025, so profit recovery and cash generation moved in different directions.

By quarter, Q3 2025 revenue was KRW 29.1 billion with operating profit of KRW 3.65 billion and controlling-shareholder net profit of KRW 3.24 billion.

In Q4 2025, revenue was KRW 28.4 billion (down 2.4% from the prior quarter), operating profit KRW 3.03 billion (down 17.0%) and controlling-shareholder net profit KRW 5.35 billion (up 65.3%). The reason net profit rose while operating profit fell in Q4 2025 is a point to trace in the full filing text.

Q1 2026 revenue was KRW 29.5 billion (up 3.9%), operating profit KRW 3.98 billion (up 31.4%) and controlling-shareholder net profit KRW 3.63 billion (down 32.3%).

Q2 2026 revenue of KRW 32.3 billion (up 9.6%) was the highest of the last five quarters, with operating profit of KRW 5.26 billion (up 32.2%) and controlling-shareholder net profit of KRW 4.82 billion (up 32.9%).

Q3 2026 revenue was KRW 29.8 billion (down 7.6% from the prior quarter and up 2.6% year on year), operating profit KRW 3.56 billion (down 32.3% from the prior quarter and down 2.4% year on year), and controlling-shareholder net profit KRW 3.14 billion (down 3.1% year on year). Controlling-shareholder net profit for the last four quarters totals KRW 16.9 billion.

05

Industry analysis

A domestic reagent market worth roughly KRW 350 billion a year was estimated in coverage from around 2013. In the same coverage, the company's estimated share of sales was 15.9%, and it was described as a top-two player at the time.

Coverage from around 2017 cited a 19% share and described the company as the market leader. The same period's reporting said most domestic reagent demand is met by imports, with a domestic substitution ratio of only about 20%, and the company planned to localize about 120 items a year.

Demand comes from corporate labs, hospitals, universities and pharmaceutical research units, and rising R&D budgets are a tailwind. Reagents have few substitutes and therefore high import dependence, but selling prices are linked to the exchange rate, which limits the effect on margins.

Imported goods and raw materials were once described as about 35% of sales, so currency moves affect the cost side as well. Among the three-company oligopoly, the company has been described as the share leader.

On the cycle, the demand driver is research and government-funded spending, and expanded government projects were cited as a demand factor in Q1 2026 (FnGuide, Q1 2026).

06

Outlook

No formal company guidance was identified for this report, so the outlook rests on confirmed facts. The most direct demand driver is expanded government-funded projects, which a FnGuide summary of Q1 2026 cited as a reason for higher reagent demand.

Q2 2026 posted revenue of KRW 32.3 billion and operating profit of KRW 5.26 billion, a high level for the window, while Q3 2026 slowed to KRW 29.8 billion in revenue and KRW 3.56 billion in operating profit. Whether demand holds at the Q2 level from Q4 onward is therefore the first checkpoint.

The battery-precursor subsidiary was described in coverage from around 2013 as a growth option tied to the expansion of electric vehicles, but how much it contributes to group profit should be traced in the disclosed segment data.

Its feedstock cost is a large share of its revenue, so metal price swings can affect its margin. For the new businesses mentioned earlier, HPLC solvents, food additives and cosmetic materials, it is worth checking whether the filings break out their revenue.

R&D spending was described at about 5% of sales in coverage from around 2017, so the pace of domestic substitution is a variable for medium-term sales. The next annual checkpoint is the operating margin and segment commentary in the 2026 annual report.

On a quarterly basis, whether Q1 2027 operating profit exceeds the KRW 3.98 billion posted in Q1 2026 will show whether the recovery is holding.

07

Valuation

PER
6.3×
PBR
0.6×
ROE
9.2%
EPS
₩2,362
BPS
₩26,750
Dividend per share
₩475

The price-to-book ratio sits well below 1x, meaning the stock trades at a steep discount to net asset value rather than a premium. On the price-to-earnings ratio, the last four quarters of controlling-shareholder net profit totaling KRW 16.9 billion also place the multiple in the lower range.

However, controlling-shareholder net profit of KRW 13.5 billion in 2025 is close to the KRW 13.7 billion of 2022, and Q3 2026 profit fell year on year, so the recovery is partial.

The dividend yield rose on disclosed data from 2023 through 2025, which means the payout is larger relative to the price even though profit has not grown much from its earlier peak. Interpretation should focus on the pace of profit recovery and the dividend policy, not a comparison with past share prices.

The drop in operating cash flow to KRW 9.97 billion in 2025 is a reason to check cash generation against reported earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Oligopoly position in domestic reagents

Domestic reagents have been described as a three-company oligopoly, with the company reported as the share leader (coverage around 2017). Supplying about 5,000 domestic and about 25,000 global-brand reagents supports product breadth. In a market with low domestic substitution, adding items is a route to medium-term sales growth.

Quarterly profit recovery in 2026

Q1 2026 operating profit of KRW 3.98 billion rose 31.4% from the prior quarter, and Q2 2026 operating profit of KRW 5.26 billion was the highest of the last five quarters. Q2 revenue of KRW 32.3 billion was also the highest in that period.

The rebound from KRW 8.48 billion in 2024 to KRW 11.2 billion in 2025 carried into the first half of 2026, which supports the bullish reading.

Balance sheet headroom

The debt ratio fell to 14.7% at the end of 2025 from 18.5% in 2022, and total equity is KRW 183.6 billion. Total liabilities of KRW 27.1 billion keep borrowing burden small. The balance sheet gives room for R&D, domestic substitution investment and support for subsidiaries.

09

Bear factors

Earnings still below 2022 levels

Operating profit was KRW 11.2 billion in 2025, against KRW 11.6 billion in 2022. Controlling-shareholder net profit was KRW 13.5 billion in 2025, against KRW 13.7 billion in 2022. Revenue reached KRW 108.1 billion in 2025, but profit has not yet exceeded its earlier peak, which is the core bearish point.

Q3 2026 slowdown

Q3 2026 revenue of KRW 29.8 billion fell 7.6% from the prior quarter, and operating profit of KRW 3.56 billion was down 2.4% year on year. Controlling-shareholder net profit of KRW 3.14 billion was down 3.1% year on year. Continuity of the Q2 recovery weakened in Q3, which is the bearish factor.

Weaker cash generation and quarterly volatility

Operating cash flow fell from KRW 12.8 billion in 2022 to KRW 9.97 billion in 2025. Controlling-shareholder net profit moved from KRW 5.35 billion in Q4 2025 to KRW 3.63 billion in Q1 2026, showing wide quarterly swings. Weaker conversion of profit into cash and large quarterly variation are the bearish factors.

10

Risk factors

Exchange rate and imported inputs

Imports of goods and raw materials were once described as about 35% of sales (coverage around 2013). Selling prices are linked to the exchange rate, which limits margin effects according to that same coverage. Still, timing gaps between cost moves and price pass-through remain a source of quarterly earnings swings.

Dependence on policy and budgets

Higher reagent demand in Q1 2026 was attributed to expanded government-funded projects (FnGuide, Q1 2026). A change in R&D budgets or government science spending could shift demand.

Demand is spread across corporate labs, hospitals, universities and pharmaceutical firms, but volatility rises as public budgets take a larger share.

Small-cap liquidity and subsidiary business

With market capitalization of KRW 106.6 billion, the stock is a small cap with limited trading depth. Headcount was reported at 206 as of June 30, 2026 (JobKorea company information).

The battery-precursor subsidiary carries a high raw-material share, so it can be sensitive to metal prices and electric-vehicle demand (coverage around 2013).

11

What to watch next

  1. Around January 2027 (typical timing; confirm via company filing)

    Q4 2026 preliminary results. The checkpoints are whether the Q3 operating profit slowdown continues into Q4 and whether quarterly revenue holds near the KRW 32.3 billion of Q2 2026.

  2. By March 31, 2027

    Filing of the 2026 annual report. The checks are whether the annual operating margin exceeds 10.3% from 2025, whether operating cash flow rebounds from KRW 9.97 billion, and how the battery-precursor subsidiary's contribution is described.

  3. Around the 2027 annual general meeting in March

    Dividend decision. The checks are whether the dividend yield holds at the 2025 disclosed level and whether the payout moves in line with profit recovery.

  4. By May 15, 2027

    Q1 2027 quarterly report. The checks are whether operating profit exceeds KRW 3.98 billion from Q1 2026 and whether government-project demand continues.

12

Overall view

Daejung Chemicals & Metals has been described as a leading player within a domestic reagent oligopoly, and its disclosed 2025 revenue and operating profit both rose.

Q2 2026 results were the strongest of the last five quarters, but Q3 2026 operating profit and controlling-shareholder net profit both edged down year on year. Earnings have returned close to the 2022 level without surpassing the earlier peak.

Operating cash flow fell to KRW 9.97 billion in 2025, so cash generation weakened relative to profit. The balance sheet has room, with a 14.7% debt ratio and total equity of KRW 183.6 billion.

The bullish case cites government-project demand, product expansion and financial capacity, while the bearish case cites the Q3 slowdown, weaker cash flow and quarterly volatility. The next checkpoints are the preliminary Q4 2026 results and the operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. jobkorea.co.kr
  2. m.itooza.com
  3. sedaily.com
  4. m.itooza.com
  5. m.edaily.co.kr
  6. pinpointnews.co.kr
  7. saramin.co.kr
  8. newsquest.co.kr
  9. edaily.co.kr
  10. jobkorea.co.kr
  11. comp.fnguide.com
  12. catch.co.kr
  13. jobkorea.co.kr
  14. m.jobkorea.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis